GBMs are rapidly fatal and kill close to 14,000 patients annually in the US alone. The goal of this proposal is to therapeutically exploit a newly isolated pure population of neural-like stem cells (NLSCs) that we recently derived from pericytes and can thus potentially be a source of autologous transplantation. The objectives of our application are to use an innovative remote-controllable stem cell-based platform to allow us to non-invasively activate NLSC production of a novel highly toxic targeted bacterial cytotoxin at the time and place of our choosing. The central hypothesis to be tested is that we can therapeutically exploit our NLSCs using image-guided HIFU in an innovative way to mildly heat tumor tissue at the depth of our choosing and induce a novel therapeutic production controlled by the heat shock protein 70 promoter (pHSP70). To test this hypothesis, 2 specific aims will be performed: (Specific Aim 1) To demonstrate tumor tropism and safety of peripherally isolated NLSCs. (Specific Aim 2) To demonstrate the feasibility of using image-guided HIFU remote activation to induce a TQM13-CTX, a novel targeted anti-GBM therapeutic that targets the tumor-restricted IL13R? Delivery of therapeutic agents specifically to tumor cells but not to the surrounding normal brain tissue using novel stem cell-based therapies offers hope against GBM, an invariably fatal disease. Thus, this proposal has strong translational relevance.

Public Health Relevance

High grade malignant gliomas are the leading cause of primary brain cancer deaths, afflicting close to 20,000 patients annually in the United States alone. We are proposing to create an innovative, clinically relevant anti-tumor strategy using novel stem cells and remote controlled therapeutic activation with potential to eradicate infiltrating tumor cells and prevent brain tumor recurrence while causing no collateral damage to normal brain. Our approach promises to significantly improve therapy against malignant brain cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA179072-04
Application #
9565494
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Welch, Anthony R
Project Start
2017-09-01
Project End
2021-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Andreotti, Julia P; Prazeres, Pedro H D M; Magno, Luiz A V et al. (2018) Neurogenesis in the postnatal cerebellum after injury. Int J Dev Neurosci 67:33-36
Prazeres, Pedro H D M; Turquetti, Anaelise O M; Azevedo, Patrick O et al. (2018) Perivascular cell ?v integrins as a target to treat skeletal muscle fibrosis. Int J Biochem Cell Biol 99:109-113
Prazeres, Pedro H D M; Almeida, Viviani M; Lousado, Luiza et al. (2018) Macrophages Generate Pericytes in the Developing Brain. Cell Mol Neurobiol 38:777-782
Costa, Matheus A; Paiva, Ana E; Andreotti, Julia P et al. (2018) Pericytes constrict blood vessels after myocardial ischemia. J Mol Cell Cardiol 116:1-4
Silva, Walison N; Prazeres, Pedro H D M; Paiva, Ana E et al. (2018) Macrophage-derived GPNMB accelerates skin healing. Exp Dermatol 27:630-635
Silva, Walison N; Leonel, Caroline; Prazeres, Pedro H D M et al. (2018) Role of Schwann cells in cutaneous wound healing. Wound Repair Regen 26:392-397
Paiva, Ana E; Lousado, Luiza; Guerra, Daniel A P et al. (2018) Pericytes in the Premetastatic Niche. Cancer Res 78:2779-2786
Guerra, Daniel A P; Paiva, Ana E; Sena, Isadora F G et al. (2018) Adipocytes role in the bone marrow niche. Cytometry A 93:167-171
Guerra, Daniel A P; Paiva, Ana E; Sena, Isadora F G et al. (2018) Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome. Angiogenesis :
Santos, G S P; Prazeres, P H D M; Mintz, A et al. (2018) Role of pericytes in the retina. Eye (Lond) 32:483-486

Showing the most recent 10 out of 33 publications